Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea.

Supernus is developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders. Supernus Pharmaceuticals was incorporated in Delaware, commenced operations in 2005, and became publicly traded in 2012.

Our principal executive offices are located in Rockville, Maryland.